Leerink Affirms Amicus Therapeutics (FOLD) at 'Outperform' Following Positive CHMP Opinion on Galafold
Tweet Send to a Friend
Leerink reaffirms its Outperform rating and $17 price target on Amicus Therapeutics (Nasdaq: FOLD) after the company received a positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
